Glycosylation End Products, Advanced
Research News and Information

Sunday, November 22, 2009

The podocyte in diabetic kidney disease.

12 Oct 2009 Approaching epidemic levels, diabetic kidney disease (DKD) is now the leading cause of end-stage renal disease (ESRD). Microalbuminuria is an early clinical marker of DKD that results from damage to the glomerular filtration barrier at the level of ... Read more...

Hepatocyte growth factor prevents advanced glycation end products-induced injury and oxidative stress through a PI3K/Akt-dependent pathway in human endothelial cells.

20 Sep 2009 AIMS: Advanced glycation end products (AGEs) trigger an oxidative reaction which then accelerates endothelial cell apoptosis; this is a critical event in the process of diabetic vascular complications. We previously demonstrated that hepatocyte ... Read more...

[Usefulness of metformin in diabetes-related bone disease]

30 Aug 2009 Accumulative evidence shows that type 2 diabetes patients have high fracture rate in spite of the absence of bone mineral density (BMD) reduction. The etiology and treatment of diabetes-related bone disease have recently attracted widespread ... Read more...

Latest indexed articles for 'Glycosylation End Products, Advanced'

These are the very latest articles for this heading:

• The podocyte in diabetic kidney disease. 12 Oct 2009
• Hepatocyte growth factor prevents advanced glycation end products-induced injury and oxidative stress through a PI3K/Akt-dependent pathway in human endothelial cells. 20 Sep 2009
• [Usefulness of metformin in diabetes-related bone disease] 30 Aug 2009
• [Poor bone quality in diabetes and arterioscelerosis] 30 Aug 2009
• Advanced glycation end product accumulation in rho(0) cells without a functional respiratory chain. 30 Aug 2009
• Reduced formation of advanced glycation endproducts via interactions between glutathione peroxidase 3 and dihydroxyacetone kinase 1. 24 Aug 2009
• Methylglyoxal: possible link between hyperglycaemia and immune suppression? 22 Aug 2009
• Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults. 11 Aug 2009
• Advanced glycation of the Arg-Gly-Asp (RGD) tripeptide motif modulates retinal microvascular endothelial cell dysfunction. 3 Aug 2009
• [Biochemical markers of bone turnover. New aspect. Bone collagen metabolism: new biological markers for estimation of bone quality] 30 Jul 2009
• Metabolic memory: implications for diabetic vascular complications. 30 Jul 2009
• Inhibitors of aldose reductase and formation of advanced glycation end-products in moutan cortex (Paeonia suffruticosa). 30 Jul 2009
• Methylglyoxal contributes to the development of insulin resistance and salt sensitivity in Sprague-Dawley rats. 30 Jul 2009
• Metabolism-induced oxidative stress is a mediator of glucose toxicity in HT22 neuronal cells. 22 Jul 2009
• Advanced glycation end products and lipopolysaccharide synergistically stimulate proinflammatory cytokine/chemokine production in endothelial cells via activation of both mitogen-activated protein kinases and nuclear factor-kappaB. 21 Jul 2009
• Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions. 17 Jul 2009
• Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats. 13 Jul 2009
• Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. 13 Jul 2009
• Impaired transcription factor interplay in addition to advanced glycation end products suppress podocalyxin expression in high glucose-treated human podocytes. 13 Jul 2009
• Advanced glycation end products inhibit the expression of collagens type I and III by human gingival fibroblasts. 29 Jun 2009

See a longer list of these articles.

Technical information about 'Glycosylation End Products, Advanced'

Definition: Products derived from the nonenzymatic reaction of glucose and proteins in vivo that exhibit a yellow-brown pigmentation and an ability to participate in protein-protein cross-linking. These substances are involved in biological processes relating to protein turnover and it is believed that their excessive accumulation contributes to the chronic complications of diabetes mellitus.

Registry Number: 0

Descriptor UI: D017127

Alternative terms: Glycosylation End Products, Advanced; Advanced Glycosylation End Products; Glycation End Products, Advanced; Advanced Glycation End Products;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D02.415;

History Note: 93

Technical Notes: DF: GEPA